Hubei Jumpcan Pharmaceutical Co Ltd (600566) - Total Liabilities
Based on the latest financial reports, Hubei Jumpcan Pharmaceutical Co Ltd (600566) has total liabilities worth CN¥3.19 Billion CNY (≈ $467.37 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hubei Jumpcan Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Hubei Jumpcan Pharmaceutical Co Ltd - Total Liabilities Trend (1998–2025)
This chart illustrates how Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Hubei Jumpcan Pharmaceutical Co Ltd asset portfolio.
Hubei Jumpcan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hubei Jumpcan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The New India Assurance Company Limited
NSE:NIACL
|
India | Rs818.45 Billion |
|
Life360, Inc. Common Stock
NASDAQ:LIF
|
USA | $438.49 Million |
|
Seabridge Gold Inc.
TO:SEA
|
Canada | CA$650.17 Million |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
USA | $1.06 Billion |
|
Jiangsu Changshu Rural Commercial Bank Co Ltd
SHG:601128
|
China | CN¥384.66 Billion |
|
Shenzhen Kstar Science & Technology Co Ltd
SHE:002518
|
China | CN¥3.03 Billion |
|
Multistrada Arah Sarana Tbk
JK:MASA
|
Indonesia | Rp116.72 Million |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
China | CN¥18.98 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Hubei Jumpcan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 600566 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Jumpcan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Jumpcan Pharmaceutical Co Ltd (1998–2025)
The table below shows the annual total liabilities of Hubei Jumpcan Pharmaceutical Co Ltd from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.07 Billion ≈ $448.89 Million |
-17.83% |
| 2024-12-31 | CN¥3.73 Billion ≈ $546.27 Million |
-21.82% |
| 2023-12-31 | CN¥4.77 Billion ≈ $698.71 Million |
+31.59% |
| 2022-12-31 | CN¥3.63 Billion ≈ $530.99 Million |
+20.96% |
| 2021-12-31 | CN¥3.00 Billion ≈ $438.99 Million |
+8.99% |
| 2020-12-31 | CN¥2.75 Billion ≈ $402.80 Million |
+7.52% |
| 2019-12-31 | CN¥2.56 Billion ≈ $374.64 Million |
+9.43% |
| 2018-12-31 | CN¥2.34 Billion ≈ $342.34 Million |
+3.48% |
| 2017-12-31 | CN¥2.26 Billion ≈ $330.82 Million |
+73.89% |
| 2016-12-31 | CN¥1.30 Billion ≈ $190.25 Million |
+48.99% |
| 2015-12-31 | CN¥872.59 Million ≈ $127.69 Million |
-17.97% |
| 2014-12-31 | CN¥1.06 Billion ≈ $155.66 Million |
+23.40% |
| 2013-12-31 | CN¥862.04 Million ≈ $126.14 Million |
+71.70% |
| 2012-12-31 | CN¥502.07 Million ≈ $73.47 Million |
+15.42% |
| 2011-12-31 | CN¥435.00 Million ≈ $63.65 Million |
+26.86% |
| 2010-12-31 | CN¥342.89 Million ≈ $50.18 Million |
+6.04% |
| 2009-12-31 | CN¥323.37 Million ≈ $47.32 Million |
-0.02% |
| 2008-12-31 | CN¥323.43 Million ≈ $47.33 Million |
+6.57% |
| 2007-12-31 | CN¥303.49 Million ≈ $44.41 Million |
+0.93% |
| 2006-12-31 | CN¥300.69 Million ≈ $44.00 Million |
+19.34% |
| 2005-12-31 | CN¥251.96 Million ≈ $36.87 Million |
+12.49% |
| 2004-12-31 | CN¥223.98 Million ≈ $32.78 Million |
+21.78% |
| 2003-12-31 | CN¥183.92 Million ≈ $26.91 Million |
+24.13% |
| 2002-12-31 | CN¥148.17 Million ≈ $21.68 Million |
+11.34% |
| 2001-12-31 | CN¥133.08 Million ≈ $19.47 Million |
+59.61% |
| 2000-12-31 | CN¥83.37 Million ≈ $12.20 Million |
+17.06% |
| 1999-12-31 | CN¥71.23 Million ≈ $10.42 Million |
-8.44% |
| 1998-12-31 | CN¥77.79 Million ≈ $11.38 Million |
-- |
About Hubei Jumpcan Pharmaceutical Co Ltd
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicines in China. The company offers drugs in the fields of pediatrics, respiratory system, digestive system, and gynecology. It is also involved in daily chemical product sales; and wholesale and retail pharmaceuticals. The company is headquartered in Taixing, China.